Padhi Dikshaa, Govindaraju Thimmaiah
Bioorganic Chemistry Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur P.O., Bengaluru, Karnataka 560064, India.
J Med Chem. 2022 May 26;65(10):7088-7105. doi: 10.1021/acs.jmedchem.2c00335. Epub 2022 May 13.
The heterogeneity and complex nature of Alzheimer's disease (AD) is attributed to several genetic risk factors and molecular culprits. The slow pace and increasing failure rate of conventional drug discovery has led to the exploration of complementary strategies based on repurposing approved drugs to treat AD. Drug repurposing (DR) is a cost-effective, low-risk, and efficient approach for identifying novel therapeutic candidates for AD treatment. Similarly, hybrid drug design through the integration of distinct pharmacophores from known or failed drugs and natural products is an interesting strategy to target the multifactorial nature of AD. In this Perspective, we discuss the potential of DR and highlight promising drug candidates that can be advanced for clinical trials, backed by a detailed discussion on their plausible mechanisms of action. Our article fosters research on the hidden potential of DR and hybrid drug design with the goal of unravelling new drugs and targets to tackle AD.
阿尔茨海默病(AD)的异质性和复杂性归因于多种遗传风险因素和分子病因。传统药物研发的缓慢进程和不断增加的失败率促使人们探索基于重新利用已批准药物来治疗AD的补充策略。药物重新利用(DR)是一种经济高效、低风险且有效的方法,用于识别治疗AD的新型候选药物。同样,通过整合已知或失败药物及天然产物中不同的药效基团进行杂交药物设计,是针对AD多因素性质的一种有趣策略。在这篇观点文章中,我们讨论了DR的潜力,并重点介绍了有望推进到临床试验阶段的候选药物,同时对其合理的作用机制进行了详细讨论。我们的文章促进了对DR和杂交药物设计潜在价值的研究,目标是揭示治疗AD的新药物和靶点。